A meta-analysis by Wang et al. \[[@CR1]\] assessing hypertension risk with ramucirumab use in patients with cancer was recently published in *Clinical Drug Investigation*. The authors concluded that ramucirumab treatment was associated with a significant increase in hypertension risk in cancer patients, and warned that treatment efficacy may be reduced due to the need to manage hypertension.

We acknowledge hypertension as an adverse reaction for ramucirumab. This is highlighted in the compound's package insert. However, the presentation by Wang et al. of the clinical severity of these events is misleading.

An analysis of pooled data was performed across six Phase III trials (ramucirumab *N* = 2748, placebo *N* = 2248). In this analysis, 21.3 % (*n* = 585) of patients taking ramucirumab experienced hypertension of any grade during treatment, versus 7.4 % (*n* = 167) for patients taking placebo. This translates to an increase of 13.9 % in the number of patients developing any grade hypertension, or about 1 in 7. More severe hypertension (≥Grade 3) was seen in 9 % (*n* = 246) of patients taking ramucirumab, and 2.5 % (*n* = 57) of patients taking placebo, a 6.5 % increase, or approximately 1 in 15 patients. These percentages coincide relatively well with the data stated in the Wang et al. meta-analysis. However, of those patients experiencing hypertension, only eight cases (\<2 %) led to discontinuation of any study treatment, showing that the hypertension was manageable.

These additional data suggest that although hypertension is a recognized adverse event in ramucirumab clinical trials, it was manageable and resulted in low rates of discontinuation across six multinational clinical phase 3 trials. Therefore, the suggestion by Wang et al. that hypertension can have an effect on treatment efficacy is unsupported by data.
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